Literature DB >> 1524761

Renin-aldosterone relationships in pregnancy-induced hypertension.

M A Brown1, V C Zammit, D A Mitar, J A Whitworth.   

Abstract

The relationship between plasma renin (PRC) and aldosterone (PAC) concentrations was determined in 83 normal third trimester pregnant women (P), 50 women with pregnancy-induced hypertension (PIH), and 80 age-matched nonpregnant women not taking oral contraceptives (NP). Normal pregnant women had a slightly higher 24-h urine sodium: creatinine ratio than the other groups (P less than .001) (NP: 10 +/- 4 v P: 15 +/- 8 v PIH: 12 +/- 7; mean +/- SD). Both PRC and PAC were higher in normal pregnant women as was the ratio PAC:PRC [normal pregnant 195 (158 to 337) v nonpregnant 130 (101 to 209), median (interquartile range); P less than .001]. This was accompanied by a slightly reduced slope (sensitivity) of the logPRC-logPAC relationship in normal pregnant women (P less than .05). Women with PIH had reduced PRC and PAC compared with normal pregnant women but a two-fold greater increase in PAC:PRC ratio [PIH 411 (277 to 598) v normal pregnancy 195 (158 to 337), P less than .001], with a rise in the slope (sensitivity) of the logPRC-logPAC relationship in women with PIH (P less than .001). Thus there is proportionately greater aldosterone release in the third trimester of normal pregnancy than in nonpregnant women. This preferential increase in aldosterone may be due to altered adrenal sensitivity to angiotensin II or may reflect enhanced nonangiotensin stimulation of aldosterone during pregnancy. Women with PIH have reduced PRC and PAC but relatively greater stimulation of aldosterone than normal pregnant women, possibly due to enhanced sensitivity of the adrenal glands to angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1524761     DOI: 10.1093/ajh/5.6.366

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  14 in total

1.  Renin-Angiotensin-Aldosterone Profiles in Pregnant Women With Chronic Hypertension.

Authors:  Line Malha; Cristina P Sison; Geraldine Helseth; Jean E Sealey; Phyllis August
Journal:  Hypertension       Date:  2018-06-25       Impact factor: 10.190

2.  Renin angiotensin signaling in normal pregnancy and preeclampsia.

Authors:  Roxanna A Irani; Yang Xia
Journal:  Semin Nephrol       Date:  2011-01       Impact factor: 5.299

Review 3.  The role of RAS in the pathogenesis of preeclampsia.

Authors:  Dinesh M Shah
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

4.  The renin-aldosterone response to stimulation and suppression during normal pregnancy.

Authors:  Rhonda Bentley-Lewis; Steven W Graves; Ellen W Seely
Journal:  Hypertens Pregnancy       Date:  2005       Impact factor: 2.108

Review 5.  Urinary serine proteases and activation of ENaC in kidney--implications for physiological renal salt handling and hypertensive disorders with albuminuria.

Authors:  Per Svenningsen; Henrik Andersen; Lise H Nielsen; Boye L Jensen
Journal:  Pflugers Arch       Date:  2014-12-09       Impact factor: 3.657

Review 6.  Renin-angiotensin system in pre-eclampsia: everything old is new again.

Authors:  Julia J Spaan; Mark A Brown
Journal:  Obstet Med       Date:  2012-12-06

Review 7.  The functional role of the renin-angiotensin system in pregnancy and preeclampsia.

Authors:  R A Irani; Y Xia
Journal:  Placenta       Date:  2008-08-08       Impact factor: 3.481

Review 8.  The biology of preeclampsia.

Authors:  Keizo Kanasaki; Raghu Kalluri
Journal:  Kidney Int       Date:  2009-08-05       Impact factor: 10.612

9.  Renal function in normal and disordered pregnancy.

Authors:  Wael Hussein; Richard A Lafayette
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-01       Impact factor: 2.894

10.  The relationship between aldosterone to renin ratio and RI value of the uterine artery in the preeclamptic patient vs. normal pregnancy.

Authors:  Euy Hyuk Kim; Jay Hak Lim; Young Han Kim; Yong Won Park
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.